Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
317 hedge funds and large institutions have $9.71B invested in Apellis Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 100 increasing their positions, 120 reducing their positions, and 31 closing their positions.
123% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 31
38% more call options, than puts
Call options by funds: $229M | Put options by funds: $166M
33% more capital invested
Capital invested by funds: $7.28B → $9.71B (+$2.43B)
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
13% more funds holding
Funds holding: 281 → 317 (+36)
4.91% less ownership
Funds ownership: 96.42% → 91.51% (-4.9%)
17% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 120
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$214M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$181M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$45.8M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$41.3M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$40.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$251M |
| 2 |
BlackRock
New York
|
-$165M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$139M |
| 4 |
State Street
Boston,
Massachusetts
|
-$60.1M |
| 5 |
Jennison Associates
New York
|
-$55.4M |
APLS Hedge Fund Activity: Q2 2023 in Review
317 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2023, worth a combined $9.71B — up 33% from $7.28B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new APLS positions and 31 closed out — a net gain of 38 holders — while 100 added to existing stakes and 120 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $214M. The largest seller was Janus Henderson Group, cutting an estimated $251M.
- 317 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2023, up from 281 in Q1 2023.
- Funds reported $9.71B of Apellis Pharmaceuticals stock for Q2 2023, up 33% quarter-over-quarter.
- 69 funds opened new Apellis Pharmaceuticals positions in Q2 2023 and 31 closed out, a net change of +38 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2023 was T. Rowe Price Associates, an estimated $214M added.
- The largest Apellis Pharmaceuticals seller in Q2 2023 was Janus Henderson Group, an estimated $251M sold.
Based on aggregated 13F filings for Q2 2023.